These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 26235742

  • 1. JNK is required for maintaining the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells.
    Liu Y, Zhang X, Wang J, Yang J, Tan WF.
    Acta Pharmacol Sin; 2015 Sep; 36(9):1099-106. PubMed ID: 26235742
    [Abstract] [Full Text] [Related]

  • 2. Twist1 and Snail link Hedgehog signaling to tumor-initiating cell-like properties and acquired chemoresistance independently of ABC transporters.
    Kong Y, Peng Y, Liu Y, Xin H, Zhan X, Tan W.
    Stem Cells; 2015 Apr; 33(4):1063-74. PubMed ID: 25588661
    [Abstract] [Full Text] [Related]

  • 3. Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells.
    Okada M, Shibuya K, Sato A, Seino S, Watanabe E, Suzuki S, Seino M, Kitanaka C.
    Oncol Rep; 2013 Oct; 30(4):1957-64. PubMed ID: 23912840
    [Abstract] [Full Text] [Related]

  • 4. Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation.
    Okada M, Shibuya K, Sato A, Seino S, Suzuki S, Seino M, Kitanaka C.
    Oncotarget; 2014 Jul 15; 5(13):5100-12. PubMed ID: 24947996
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest.
    Kuntzen C, Sonuc N, De Toni EN, Opelz C, Mucha SR, Gerbes AL, Eichhorst ST.
    Cancer Res; 2005 Aug 01; 65(15):6780-8. PubMed ID: 16061660
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells.
    Yoon CH, Kim MJ, Kim RK, Lim EJ, Choi KS, An S, Hwang SG, Kang SG, Suh Y, Park MJ, Lee SJ.
    Oncogene; 2012 Nov 01; 31(44):4655-66. PubMed ID: 22249269
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inflammatory pathway analysis using a high content screening platform.
    Bertelsen M, Sanfridson A.
    Assay Drug Dev Technol; 2005 Jun 01; 3(3):261-71. PubMed ID: 15971988
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis.
    Alexaki VI, Javelaud D, Mauviel A.
    Pigment Cell Melanoma Res; 2008 Aug 01; 21(4):429-38. PubMed ID: 18541008
    [Abstract] [Full Text] [Related]

  • 17. Requirement of JNK signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells.
    Seino M, Okada M, Shibuya K, Seino S, Suzuki S, Ohta T, Kurachi H, Kitanaka C.
    Anticancer Res; 2014 Sep 01; 34(9):4723-31. PubMed ID: 25202050
    [Abstract] [Full Text] [Related]

  • 18. JNK1 protects against glucolipotoxicity-mediated beta-cell apoptosis.
    Prause M, Christensen DP, Billestrup N, Mandrup-Poulsen T.
    PLoS One; 2014 Sep 01; 9(1):e87067. PubMed ID: 24475223
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.